Eli Lilly and Company (NYSE: LLY) is listed among the 12 Best Ethical Companies to Invest in 2025. Leerink Partners and Jefferies issue bullish ratings on LLY, citing its growth potential in cutting-edge treatments like the GLP-1 receptor agonist (GLP-1RA) space. A recent JAMA study shows LLY’s ‘tirzepatide’ medication improves blood sugar control and reduces risks of dementia, stroke, and death in adults with type 2 diabetes and obesity. Jefferies maintains a ‘Buy’ rating with a price target of $1,057, while LLY is currently trading at $805.43. Eli Lilly operates globally in human pharmaceuticals and is considered one of the best ESG stocks.

Read more at Yahoo Finance: Leerink Partners and Jefferies Issue Bullish Ratings on Eli Lilly and Company (LLY)